PRESS RELEASES

Date Title and Summary View
May 2, 2018
Summary ToggleZafgen to Present at Deutsche Bank 43rd Annual Health Care Conference

BOSTON , May 02, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield,

Summary ToggleZafgen to Present at Deutsche Bank 43rd Annual Health Care Conference
May 1, 2018
Summary ToggleZafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results

BOSTON , May 01, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a

Summary ToggleZafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results
Mar 7, 2018
Summary ToggleZafgen to Present at Cowen 38th Annual Health Care Conference
BOSTON , March 07, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey
Summary ToggleZafgen to Present at Cowen 38th Annual Health Care Conference
Mar 6, 2018
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
ZGN-1061 interim data suggest compound is safe and well-tolerated; no safety signals and placebo-like side effect profile ZGN-1061 interim efficacy data indicate significant A1C lowering vs. placebo at 8 weeks   ZGN-1258 for Prader-Willi syndrome (PWS) added to the pipeline; IND enabling studies
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
Mar 1, 2018
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results
BOSTON , March 01, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results
Feb 8, 2018
Summary ToggleZafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
BOSTON , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield ,
Summary ToggleZafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Jan 5, 2018
Summary ToggleZafgen Reports Strong Clinical Progress and Updates Outlook for 2018
BOSTON, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced strong clinical progress with its lead 
Summary ToggleZafgen Reports Strong Clinical Progress and Updates Outlook for 2018
Nov 7, 2017
Summary ToggleZafgen Reports Third Quarter 2017 Financial Results
BOSTON, MA--(Marketwired - November 07, 2017) - Zafgen, Inc. ( ZFGN ), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by type 2 diabetes, rare diseases and other metabolic diseases, today announced its third quarter
Summary ToggleZafgen Reports Third Quarter 2017 Financial Results
Oct 12, 2017
Summary ToggleZafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
BOSTON , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases,  today announced that on October 9, 2017 the Company granted Jeffrey Hatfield
Summary ToggleZafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Oct 10, 2017
Summary ToggleZafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
BOSTON , Oct. 10, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases, announced today that the Company has appointed Jeffrey Hatfield as its Chief
Summary ToggleZafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer